Skip to main content

Table 3 Onabotulinumtoxin A (OBT-A) in the context of other prophylactic therapies for chronic migraine and timing of OBT-A initiation

From: Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers

Answer options n (%)
Frequency of combination of OBT-A with other prophylactic therapies
 Never 3 (4.8)
 Rarely 14 (22.2)
 Frequently 45 (71.4)
 Always 1 (1.6)
Number of prophylactic therapies used before initiating OBT-A
 0 1 (1.6)
 1 2 (3.2)
 2-3 22 (34.9)
 > 3 38 (60.3)
Rating of tolerability profile of OBT-A vs. oral prophylactic therapies
 More favorable 57 (90.5)
 Comparable 5 (7.9)
 Less favorable 1 (1.6)
Rating of efficacy/safety ratio of OBT-A vs. oral prophylactic therapies
 More favorable 44 (69.8)
 Comparable 18 (28.6)
 Less favorable 1 (1.6)
Impression of greater efficacy of OBT-A when initiated early in the course of chronic migraine
 Never 0
 Rarely 9 (14.3)
 Frequently 51 (80.9)
 Always 3 (4.8)
Recommendation of OBT-A as first-line treatment based on the pharmacological profile
 Yes 30 (47.6)
 No 33 (52.4)